The FDA announced on June 12 that it has approved pembrolizumab for adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1.
In a recent study presented at the Hematology/Oncology Pharmacy Association annual conference, researchers examined the use of opioids in patients with head and neck squamous cell carcinoma while undergoing...
